{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:24:44Z","timestamp":1768929884674,"version":"3.49.0"},"reference-count":13,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>In Minnesota, medical cannabis was approved for use in 2014. From July 2015 to February 2019, our center certified 103 pediatric and young adult patients for the use of medical cannabis under the qualifying conditions of cancer and treatment-related symptoms. Here, we provide a review of the literature on medical cannabis use in pediatric and young adult cancer patients. We also provide demographic data on our patients certified for medical cannabis. The most common diagnoses were leukemia\/lymphoma (36%), brain tumors (37%), and malignant solid tumors (26%). The most common indications were chemotherapy-related nausea, pain, and cancer cachexia. The age range at certification was 1.4\u201328.7 years (median 15.3 years). The time from cancer diagnosis to certification ranged from 0.5\u2013197 months (median 8.9 months). The majority (94%) were certified during their first line of treatment. In the 32 patients who died from recurrent or progressive cancer, the time from certification to death was 1.3\u201330.3 months (median 4.4 years). Despite requesting certification, a subset (24%) never had medical cannabis dispensed. In our experience, pediatric and young adult oncology patients are interested in medical cannabis to help manage treatment-related symptoms. Ongoing analysis of this data will identify the therapeutic efficacy of medical cannabis.<\/jats:p>","DOI":"10.3390\/children6060079","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T11:24:45Z","timestamp":1560770685000},"page":"79","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Medical Cannabis Certification in a Large Pediatric Oncology Center"],"prefix":"10.3390","volume":"6","author":[{"given":"Mary M.","family":"Skrypek","sequence":"first","affiliation":[{"name":"Cancer and Blood Disorders Program, Division of Pediatric Hematology-Oncology, Children\u2019s Minnesota, 2530 Chicago Avenue South, CSC-175, Minneapolis, MN 55404, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce C.","family":"Bostrom","sequence":"additional","affiliation":[{"name":"Cancer and Blood Disorders Program, Division of Pediatric Hematology-Oncology, Children\u2019s Minnesota, 2530 Chicago Avenue South, CSC-175, Minneapolis, MN 55404, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne E.","family":"Bendel","sequence":"additional","affiliation":[{"name":"Cancer and Blood Disorders Program, Division of Pediatric Hematology-Oncology, Children\u2019s Minnesota, 2530 Chicago Avenue South, CSC-175, Minneapolis, MN 55404, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"ref_1","unstructured":"(2019, January 31). Minnesota Department of Health: Medical Cannabis. Available online: https:\/\/www.health.state.mn.us\/people\/cannabis\/index.html."},{"key":"ref_2","unstructured":"(2019, January 31). Minnesota Department of Health Medical Cannabis Program Update. Available online: https:\/\/www.health.state.mn.us\/people\/cannabis\/docs\/about\/update0119.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1377\/hlthaff.2018.05266","article-title":"Qualifying conditions of medical cannabis license holders in the United States","volume":"38","author":"Boehnke","year":"2019","journal-title":"Health Aff."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1300\/J069v13n01_05","article-title":"Marijuana as an antiemetic drug: How useful is it today? Opinions from clinical oncologists","volume":"13","author":"Schwartz","year":"1994","journal-title":"J. Addict. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11912-019-0757-7","article-title":"A comprehensive review of cannabis in patients with cancer: Availability in the USA, general efficacy, and safety","volume":"21","author":"Steele","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/13543784.2019.1561859","article-title":"Cannabis for cancer\u2013illusion or the tip of an iceberg: A review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology","volume":"28","author":"Turgeman","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics Policy Statement (2015). The Impact of Marijuana Policies on Youth: Clinical, research, and legal update. Pediatrics, 135, 584\u2013587.","DOI":"10.1542\/peds.2014-4146"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e26826","DOI":"10.1002\/pbc.26826","article-title":"Medical marijuana in pediatric oncology: A review of the evidence and implications for practice","volume":"65","author":"Ananth","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_9","first-page":"462","article-title":"Characterization of dronabinol usage in a pediatric oncology population","volume":"20","author":"Elder","year":"2015","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/0024-3205(95)00194-B","article-title":"An efficient new cannabinoid antiemetic in pediatric oncology","volume":"56","author":"Abrahamov","year":"1995","journal-title":"Life Sci."},{"key":"ref_11","first-page":"946","article-title":"Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: A double-blind, crossover trial","volume":"79","author":"Chan","year":"1987","journal-title":"Pediatrics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/adc.61.5.502","article-title":"Nabilone: An alternative antiemetic for cancer chemotherapy","volume":"61","author":"Dalzell","year":"1987","journal-title":"Arch. Dis. Child."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1691428","DOI":"10.1155\/2018\/1691428","article-title":"Cannabis sativa L. and nonpsychoactive cannabinoids: Their chemistry and role against oxidative stress, inflammation, and cancer","volume":"2018","author":"Pellati","year":"2018","journal-title":"BioMed Res. Int."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/6\/6\/79\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:58:57Z","timestamp":1760187537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/6\/6\/79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":13,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["children6060079"],"URL":"https:\/\/doi.org\/10.3390\/children6060079","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]}}}